About
Aglaia Oncology Funds is an Institutionalinvestor specializing in oncology drug development companies. Established in 2004, Aglaia has built a strong reputation for its ability to identify and mature early stage breakthrough inventions with the potential to transform cancer treatment. The team boasts decades of experience in cancer research and oncology drug development, having been involved in the creation of over 100 oncology products. Aglaia is active in its strategic and operational involvement with portfolio companies, guiding them from early screening through clinical stages, thereby derisking and maturing these ventures for licensing, acquisition, or IPO. Notable funds include the active Aglaia Oncology Fund II and Aglaia Oncology Growth Opportunity Funds.